Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Dare Bioscience, Inc. furnished a new corporate investor presentation as Exhibit 99.1 under a Regulation FD disclosure. The presentation is dated June 22, 2026 and will be used in meetings with securities market participants and others starting that same date.

The company plans to post the presentation in the Investors section of its website under “Presentations, Events & Webcasts.” The information in the presentation and in this disclosure is being furnished, not filed, so it is not subject to Section 18 liability and is not automatically incorporated into other SEC filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Regulation FD Disclosure, corporate presentation, furnished and shall not be deemed to be filed, incorporated by reference

4 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. Furnished as Exhibit 99.1 to this report"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

corporate presentation financial

"a copy of a corporate presentation of Daré Bioscience, Inc. dated June 22, 2026"

furnished and shall not be deemed to be filed regulatory

"The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be filed"

incorporated by reference regulatory

"nor shall such information be deemed to be incorporated by reference into any filing"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/22/2026 - 09:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2026

Dare Bioscience, Inc.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated June 22, 2026, which is incorporated herein by reference. The Company intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on June 22, 2026.

The Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated by reference into this report.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated June 22, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.

Dated: June 22, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Dare Bioscience (DARE) disclose in its latest 8-K?

Dare Bioscience furnished a new corporate investor presentation dated June 22, 2026 as Exhibit 99.1. The presentation supports communications with securities market participants and will be accessible through the Investors section of the company’s website under “Presentations, Events & Webcasts.”

How will Dare Bioscience (DARE) use the June 22, 2026 corporate presentation?

Dare Bioscience plans to use the June 22, 2026 corporate presentation in various meetings with securities market participants and others. It is intended as an information resource and will also be available on the company’s Investor Relations website section for broader access.

Where can investors find Dare Bioscience’s June 22, 2026 presentation?

Investors can access the June 22, 2026 Dare Bioscience corporate presentation in the Investors section of the company’s website. It will appear on the “Presentations, Events & Webcasts” page, under the heading “Presentations,” alongside other investor materials and resources.

Is Dare Bioscience’s new presentation considered filed or furnished with the SEC?

The corporate presentation attached as Exhibit 99.1 is being furnished, not filed, with the SEC. As a result, it is not subject to Section 18 of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.

Does Dare Bioscience (DARE) incorporate website information into this 8-K disclosure?

Information on Dare Bioscience’s website, or on any external website referenced in the presentation, is not incorporated by reference into this 8-K. Only documents specifically identified and incorporated by reference become part of the company’s formal SEC disclosure record.

Filing Exhibits & Attachments

42 documents